# US 2012/0252805 A1 · Novel compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252805 A1
- Document ID: US20120252805A1
- Status: Published application
- Kind: A1
- Application number: 13/516,252
- Filed: 2010-12-16
- Published: 2012-10-04
- Earliest claimed: 2009-12-18
- Assignees: GlaxoSmithKline Intellectual Property Limited
- Inventors: Deborah Chen; Kiew Ching Lee; Lamont Roscoe Terrel
- Web page: https://patentgrep.com/patent/US20120252805A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase II enzyme.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A compound of Formula (I) or a pharmaceutically acceptable salt thereof
wherein:
R1 is selected from the group consisting of:
H, halo, CN, (CH2)nNRaRa, C(O)NRaRa, C(O)ORb, NRbC(O)Rb, (CH2)mORb,
C1-C6 alkyl optionally substituted with heterocycloalkyl,
heterocycloalkyl,
C1-C6 alkynyl optionally substituted with OH, C1-C3 alkoxy, NRaRa or heterocycloalkyl,
(CH2)nRc wherein Rc is optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, C1-C3 alkyl, NRaRa and halo, and
(CH2)nRd wherein Rd is optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, C1-C3 alkyl, NRaRa and halo;
R2 is selected from the group consisting of:
H, halo, CN, C(O)NRaRa,
C1-C6 alkyl,
heterocycloalkyl,
(CH2)nRc wherein Rc is optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, (CH2)nNRaC(O)ORa, (CH2)nNRaRa, halo, C1-C4 alkyl optionally substituted with one to three F, and heterocycloalkyl optionally substituted with C(O)ORb, and
(CH2)nRd wherein Rd is optionally substituted with one or more substituents selected from the group consisting of C1-C4 alkyl, C1-C3 alkoxy, halo, heterocycloalkyl and (CH2)nNRaRa;
R3 is selected from the group consisting of:
C1-C6 alkyl optionally substituted with Rc wherein Rc is optionally substituted with halo,
heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of halo and C(O)ORb wherein Rb is optionally substituted with phenyl,
cycloalkyl,
Rc optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, NRaRa, NO2, halo, and C1-C4 alkyl optionally substituted with one to three F, and
Rd optionally substituted with one or more substituents selected from the group consisting of C1-C4 alkyl, C1-C3 alkoxy, halo and phenyl;
R4 is H, C1-C6 alkyl, C1-C3 alkoxy, halo, CN or OH;
each Ra is H or C1-C6 alkyl or both Ra groups, independently in each instance, taken together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocycloalkyl ring;
each Rb is H or C1-C6 alkyl;
each Rc is phenyl;
each Rd is heteroaryl;
each m is 1 or 2; and
each n is 0, 1, 2 or 3.

### Claim 21 (depends on 20)

A compound or salt according to claim 20, wherein R1 is C1-C3 alkyl or H.

### Claim 22 (depends on 20)

A compound or salt according to claim 20, wherein R1 is pyrazolyl.

### Claim 23 (depends on 20)

A compound or salt according to claim 20, wherein R2 is phenyl substituted with one or more substituents selected from the group consisting of dimethylamino, F, pyrrolidinyl and morpholinyl.

### Claim 24 (depends on 20)

A compound or salt according to claim 20, wherein R2 is pyridinyl substituted with dimethylamino, pyrrolidinyl or morpholinyl.

### Claim 25 (depends on 20)

A compound or salt according to claim 20, wherein R3 is phenyl optionally substituted with one or more Cl or C1-C3 alkoxy.

### Claim 26 (depends on 20)

A compound or salt according to claim 20, wherein R3 is heteroaryl optionally substituted with C1-C4 alkyl.

### Claim 27 (depends on 20)

A compound or salt according to claim 20, wherein R4 is methyl or H.

### Claim 28 (depends on 20)

A compound of Formula (I) or a salt thereof according to claim 20, which is a compound of examples 1 to 126 or a salt thereof.

### Claim 29 (depends on 20)

A pharmaceutical composition which comprises a compound according to claim 20 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

### Claim 30 (depends on 20)

A method of treatment of diseases mediated by the NADPH oxidase II enzyme NOX2 which comprises administering to a host in need thereof an effective amount of a compound according to claim 20 or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 30)

A method of treatment of diseases mediated by the NADPH oxidase II enzyme NOX2 according to claim 30, wherein the disease is Amyotrophic lateral sclerosis.

### Claim 32 (depends on 30)

A method of treatment of diseases mediated by the NADPH oxidase II enzyme NOX2 according to claim 30, wherein the host is human.

### Claim 33 (depends on 20)

A pharmaceutical composition for use in the treatment or prophylaxis of diseases mediated by the NADPH oxidase II enzyme NOX2 which comprises the compound of Formula (I) as defined in claim 20 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
